Sailing in deceptive calm: Navigating the undercurrents of essential thrombocythaemia.

ABSTRACT

The discovery of driver mutations in myeloproliferative neoplasms has significantly contributed to the management of patients with essential thrombocythaemia (ET). High-quality evidence has started to pave the way for targeted therapy. The review by Ferrer-Marín et al. further advances this discussion, highlighting how molecular profiling, including non-driver gene mutations, is set to revolutionize personalized treatment approaches for ET patients. Commentary on Ferrer-Marín et al. Essential thrombocythemia a contemporary approach with new drugs on the horizon. Br J Haematol 2024;2041605-1616.